Skip to main content

Market Overview

Arvinas: Q4 Earnings Insights

Share:

 

Shares of Arvinas (NASDAQ:ARVN) remained unaffected after the company reported Q4 results.

Quarterly Results

Earnings per share decreased 76.79% year over year to ($0.99), which missed the estimate of ($0.78).

Revenue of $2,218,000 decreased by 54.67% year over year, which missed the estimate of $6,910,000.

Outlook

Earnings guidance hasn't been issued by the company for now.

Arvinas hasn't issued any revenue guidance for the time being.

Recent Stock Performance

52-week high: $92.77

52-week low: $19.68

Price action over last quarter: Up 256.56%

Company Profile

Arvinas Inc is a United States-based private biopharmaceutical company focused on developing first-in-class protein degradation therapeutics for cancers and other difficult-to-treat diseases. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. Its pipeline candidates include metastatic castration-resistant prostate cancer, metastatic ER-breast cancer, additional oncology indications, tauopathies, and other neurodegenerative diseases.

 

Related Articles (ARVN)

View Comments and Join the Discussion!

Posted-In: BZI-RecapsEarnings News

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com